ClinicalTrials.gg
CompletedNCT00551356IOOLUpdated Oct 31, 2007

Lispro Mix 25 vs. Glargine in Type 2 Diabetics

A Phase 3 interventional study of Insulin lispro mix 25 and Glargine in Diabetes Mellitus Type 2, sponsored by Eli Lilly and Company. Completed at 1 site in Mexico. Open to participants aged 30 Years to 75 Years. Per ClinicalTrials.gov, last updated 2007-10-31.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
53
Allocation
Randomized
Ages
30 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 — 4 open to participants now, 6 under way, 1 of them phase 3. Insulin Glargine · Diabetes Mellitus, Type 2.

Enrollment
145th of 175
53 · median 253
Started
2002
with 3 others
Phase 3
60 of 176
1 open now
Registered
38th of 176
by date
Lead sponsor
15 of 176
Eli Lilly and Company

Among the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, this one is the 145th largest by enrollment of the 175 interventional ones that give a count, is one of 4 that started in 2002, is one of 60 in phase 3, and was the 38th registered.

Diabetes Mellitus, Type 2

10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

4 of the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About Insulin Glargine

Insulin Glargine: first FDA approval 2000 (LANTUS SOLOSTAR), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 30 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

In patients with type 2 diabetes who have not been on insulin therapy before the study will achieve better glycemic control by the treatment regiment consisting of two times daily insulin lispro mix 25 than by the treatment regiment with consisting of one time daily injection of insulin glargine. Improved glycemic control will be compared by the fasting plasma glucose and blood glucose excursions 2 hours after breakfast.

Read the detailed description

The objective of this study is to investigate which type of insulin regimen is the best way to achieve best glycemic control in early type 2 diabetes. Patients with diabetes mellitus type 2 with a duration of diabetes between 1 and 10 years without previous insulin therapy will be randomized on insulin lispro mix 25 or insulin glargine therapy. Glycemic control will be compared by the between treatment difference in fasting plasma glucose and 2h postprandial blood glucose excursions (preprandial -postprandial excursions) after breakfast.

03

Conditions studied

  • Diabetes Mellitus Type 2

Keywords

  • Diabetes
  • Diabetic
  • Insulin
  • Humalog
  • Lantus
  • Glargine
  • Lispro
04

Who can participate

Ages eligible
30 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females who have type 2 diabetes between 1 and 10 years
  • Have used diet and/or maximum doses of oral antidiabetic agents (combination) for the treatment of their diabetes
  • Have not been on insulin treatment within 3 months before entry into the study
  • Have a in the range of 8.0 to 12.5% according to a local laboratory within 4 weeks prior to or at Visit 1
  • Have a below 40 kg/m²

Exclusion criteria

Exclusion Criteria:

  • Receive chronic (lasting longer than 2 weeks) systemic therapy (excluding topical and inhaled preparations) or have received such therapy within 2 weeks immediately prior to Visit 1
  • Have a known allergy to insulin
  • Have serum creatinine greater than or equal to 1.5 mg/dl as determined by a local laboratory
  • Have known proliferative retinopathy
  • Have had more than one unexplained episode of severe hypoglycemia (defined as requiring assistance of another person due to disabling hypoglycemia) within 6 months prior to entering the study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
53 participants (actual)

Study arms

  • Active comparator
    2

    Insulin glargine given SC once-daily in conjunction with oral antidiabetic medications.

    Drug: Glargine

  • Active comparator
    1

    Lispro mix 25 SC twice-daily in conjunction with oral antidiabetic medications.

    Drug: Insulin lispro mix 25

Interventions

  • DrugInsulin lispro mix 25

    Insulin lispro mix 25 given SC twice-daily in conjunction with oral antidiabetic medications.

    Also known as: Humalog Mix25

  • DrugInsulin GlargineStudies of Insulin GlargineInsulin Glargine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Insulin glargine given SC once-daily in conjunction with oral antidiabetic medications.

    Also known as: Lantus

06

What researchers measure

Primary outcomes

  1. Change from baseline to endpoint in 2h postprandial blood glucose excursion after breakfast

    Time frame: 16 weeks or end of study.

Secondary outcomes

  1. Hemoglobin A1c measured at endpoint

    Time frame: 16 weeks or end of study.

  2. Change of hemoglobin A1c from baseline to endpoint

    Time frame: 16 weeks or end of study.

  3. Glycemic control as determined by self-monitored blood glucose concentrations

    Time frame: 16 weeks or end of study.

  4. The incidence and rate of self-reported hypoglycemic episodes

    Time frame: 16 weeks or end of study.

  5. Body mass index (BMI)

    Time frame: 16 weeks or end of study.

  6. Body weight

    Time frame: 16 weeks or end of study.

  7. Total Insulin Doses

    Time frame: 16 weeks or end of study.

07

Study locations

1 site
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mexico City, Mexico
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2002 and a completion of Jul 2003. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2007
First posted
Oct 31, 2007
Start
Nov 2002
CompletionActual
Jul 2003
Last update
Oct 31, 2007
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 31, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00551356
First posted
Oct 31, 2007
Start date
Nov 2002
Completion
Jul 2003
Last update
Oct 31, 2007

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin Glargine

Start the discussion